FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	s)													
1. Name and Address of Reporting Person *- Gavin Robert M.				2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]					5. Re	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 614 MCKINLEY PLACE NE				3. Date of Earliest Transaction (Month/Day/Year) 08/07/2015					X	X Officer (give title below) Other (specify below) Senior V.P. Protein Platforms					
MINNEA	POLIS, MI	(Street) N 55413		4. If Ame	ndme	ent, Date	Orig	inal Filed(Mo	onth/Day/Year)	_X_ F	orm filed by	One Reporting	up Filing(Check Person Reporting Person	Applicable Line))
(City))	(State)	(Zip)			Table	e I -	Non-Derivat	tive Securities	Acquired,	Disposed	of, or Ben	eficially Owne	d	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed B. Code (Instr. 8) (Month/Day/Year) 2A. Transa Code (Instr. 8)				4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		of (D) Owno Trans (Instr	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			7. Nature Ownership of Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4)		
Reminder: F	Report on a s	eparate line for eac	h class of securities					Persons containe form dis	who responed in this fore	m are not i ently valid	required OMB co	to respon	nd unless the		74 (9-02)
									ed of, or Bene vertible securi		ned				
Derivative Security	2. Conversion or Exercise Price of Derivative Security		Transaction 3A. Deemed	4. If Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 93.32							(1)	07/31/2021	Common Stock	10,000		10,000	D	
Stock Option (Right to Buy)	\$ 93.32							<u>(2)</u>	07/31/2021	Common Stock	50,000		50,000	D	
Stock Option (Right to Buy)	\$ 90.25							(3)	11/30/2021	Common Stock	5,000		5,000	D	
Restricted Stock Units	<u>(4)</u>							<u>(4)</u>	<u>(4)</u>	Common Stock	5,000		5,000	D	
Stock Option (Right to Buy)	\$ 108.49	08/07/2015		A		12,500		<u>(5)</u>	08/07/2022	Common Stock	12,500	\$ 0	12,500	D	
Stock Option (Right to Buy)	\$ 108.49	08/07/2015		A		6,250		(7)	08/07/2022	Common Stock	6,250	\$ 0	6,250	D	
Restricted															

<u>(7)</u>

1,000

A

Common

1,000

\$ 0

1,000

D

Reporting Owners

<u>(6)</u>

Stock

Units

08/07/2015

D (0 N / 11)	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Gavin Robert M.							

614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413	Senior V.P. Protein Platforms	rms
Signatures		

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Robert M. Gavin pursuant to Power of Attorney filed herewith.	08/11/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
- (2) The options vest if certain performance goals are achieved for calendar 2016.
- (3) 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
- (4) Vests in full or in part if certain performance goals are achieved for calendar 2016 (previously reported in Table I).
- **(5)** 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (6) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (7) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

The undersigned hereby constitutes and appoints Brenda S. Furlow, James Hippel, Melodie R. Rose and Elizabeth M. Dunshee, or either of them acting alone, the undersigned's true and lawful attorneys-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of December, 2014.